Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Consolidated Net Income (2018 - 2025)

Historic Consolidated Net Income for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to -$13.4 million.

  • Arcturus Therapeutics Holdings' Consolidated Net Income fell 9481.38% to -$13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.7 million, marking a year-over-year decrease of 656.73%. This contributed to the annual value of -$80.9 million for FY2024, which is 17229.94% down from last year.
  • Arcturus Therapeutics Holdings' Consolidated Net Income amounted to -$13.4 million in Q3 2025, which was down 9481.38% from -$9.2 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' 5-year Consolidated Net Income high stood at $118.6 million for Q4 2022, and its period low was -$57.7 million during Q1 2021.
  • Its 5-year average for Consolidated Net Income is -$17.9 million, with a median of -$21.6 million in 2022.
  • In the last 5 years, Arcturus Therapeutics Holdings' Consolidated Net Income tumbled by 50944.83% in 2021 and then surged by 41516.0% in 2022.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Consolidated Net Income (Quarter) stood at -$37.6 million in 2021, then surged by 415.16% to $118.6 million in 2022, then plummeted by 109.84% to -$11.7 million in 2023, then crashed by 156.89% to -$30.0 million in 2024, then surged by 55.18% to -$13.4 million in 2025.
  • Its Consolidated Net Income stands at -$13.4 million for Q3 2025, versus -$9.2 million for Q2 2025 and -$14.1 million for Q1 2025.